SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
NEW YORK, Feb. 13, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Aradigm Corporation ("Aradigm") (NASDAQ:ARDM) securities between July 27, 2017 and January 8, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/aradigm-corporation?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the methodology underlying Aradigm's Linhaliq Phase III clinical trials was not well tailored to yield consistent efficacy findings or to provide data sufficient to account for discordant efficacy findings; (ii) the endpoint of the Phase III trials was unlikely to demonstrate a clinically meaningful benefit with respect to a patient population that would likely be taking the drug for a longer duration; (iii) accordingly, these studies were unlikely to support FDA approval of the Linhaliq NDA; and (iv) as a result, Aradigm's public statements were materially false and misleading at all relevant times.
On January 9, 2018, the FDA released its briefing document for the January 11, 2018 meeting of the Antimicrobial Drugs Advisory Committee to discuss the NDA for Linhaliq for the proposed indication of treatment of non-cystic fibrosis bronchiectasis. The FDA recommended Aradigm conduct “two independent trials” to provide evidence supporting the drug’s “overall demonstration of efficacy and safety.”
If you suffered a loss in Aradigm you have until March 12, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/aradigm-corporation?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
